But if a company was in the works of partnering with CytoDyn just on long acting HIV, they would have had to pay for that priviiege right? So we would have expected to have some cash payment upfront and then Livimmune would run it while CytoDyn collects 20% say? And that didn't happen. At least it wasn't announced.

Or could the deal be delayed? Once the hold is lifted, as the long acting Leronlimab drug is improved/developed, as the share price increases and CytoDyn becomes stronger financially, CytoDyn can negotiate terms with this company from a position of strength instead of now, so we delay the agreement on terms, until it is more opportune for us to do so where we exchange shares for cash, but, that would be more of a partnership than a subsidiary in only 1 indication. I think royalties works better with subsidiaries. Maybe by delaying, CytoDyn can get 30%. Just thinking outloud.